Managing patients with hematological malignancies during COVID-19 pandemic
| dc.contributor.author | Sahu, Kamal Kant | |
| dc.contributor.author | Cerny, Jan | |
| dc.date | 2022-08-11T08:08:11.000 | |
| dc.date.accessioned | 2022-08-23T15:45:48Z | |
| dc.date.available | 2022-08-23T15:45:48Z | |
| dc.date.issued | 2020-06-25 | |
| dc.date.submitted | 2020-07-08 | |
| dc.identifier.citation | <p>Sahu KK, Cerny J. Managing patients with hematological malignancies during COVID-19 pandemic. Expert Rev Hematol. 2020 Jun 25. doi: 10.1080/17474086.2020.1787147. Epub ahead of print. PMID: 32580592. <a href="https://doi.org/10.1080/17474086.2020.1787147">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 1747-4094 (Linking) | |
| dc.identifier.doi | 10.1080/17474086.2020.1787147 | |
| dc.identifier.pmid | 32580592 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/27612 | |
| dc.description.abstract | The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17th, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported [2]. Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32580592&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | This is an Accepted Manuscript of an article published in Expert Review of Hematology, posted after 12-month embargo as allowed by the publisher's author self-archiving policy at https://authorservices.taylorandfrancis.com/sharing-your-work/#. | |
| dc.subject | COVID-19 | |
| dc.subject | Cancer | |
| dc.subject | Hematology | |
| dc.subject | Pandemic | |
| dc.subject | Health Services Administration | |
| dc.subject | Hematology | |
| dc.subject | Hemic and Lymphatic Diseases | |
| dc.subject | Infectious Disease | |
| dc.subject | Neoplasms | |
| dc.subject | Oncology | |
| dc.subject | Virus Diseases | |
| dc.title | Managing patients with hematological malignancies during COVID-19 pandemic | |
| dc.type | Accepted Manuscript | |
| dc.source.journaltitle | Expert review of hematology | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1064&context=covid19&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/covid19/62 | |
| dc.legacy.embargo | 2021-06-25T00:00:00-07:00 | |
| dc.identifier.contextkey | 18421075 | |
| refterms.dateFOA | 2022-08-23T15:45:48Z | |
| html.description.abstract | <p>The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17<sup>th</sup>, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported [2]. Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge.</p> | |
| dc.identifier.submissionpath | covid19/62 | |
| dc.contributor.department | Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care |
